基本信息
产品编号: |
P10983 |
||||
产品名称: |
Propranolol |
||||
CAS: |
525-66-6 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
6个月 |
||
分子量: |
259.34 |
-20℃ |
1个月 |
||
化学名: |
|||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
|
|||
Ethanol |
|
||||
Water |
|
||||
体内(现配现用): |
|
||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
3.8559mL |
19.2797mL |
38.5594mL |
5mM |
0.7712mL |
3.8559mL |
7.7119mL |
10mM |
0.3856mL |
1.9280mL |
3.8559mL |
生物活性
产品描述 |
一种非选择性的 β-adrenergic receptor (βAR) 拮抗剂,对 β1AR 和 β2AR 具有高亲和力,Ki 值分别为 1.8nM 和 0.8nM。Propranolol 抑制[3H]-DHA 与大鼠脑膜制剂的结合,IC50 为 12 nM。Propranolol 用于高血压,嗜铬细胞瘤,心肌梗塞,心律不齐,心绞痛和肥大心肌病的相关研究。 |
|
靶点 |
12nM (βAR) |
|
体外研究 |
Propranolol (10-7M-10-3M;24 and 48 hours) increases the total ERK1/2 levels in a dose-dependent manner,and ERK1/2 activation is observed specifically at 10-5M in HemSCs.Propranolol (10-9M-10-3M;24 and 48 hours) significant decreases cell proliferation at 10-4M propranolol after 24 hours and 10-9M propranolol after 48 hours in HemSCs.Propranolol (50μM-200μM;24 hours) increases Annexin V positivity and caspase-3 activation,rapidly induces HemSC apoptosis. Western Blot Analysis |
|
Cell Line: |
HemSC cells |
|
Concentration: |
10-7M-10-3M |
|
Incubation Time: |
24 and 48 hours |
|
Result: |
Increased the total ERK1/2 levels in a dose-dependent manner. |
|
Cell Proliferation Assay |
||
Cell Line: |
HemSC cells |
|
Concentration: |
10-9M-10-3M |
|
Incubation Time: |
24 and 48 hours |
|
Result: |
Suppressed HemSC proliferation. |
|
Apoptosis Analysis |
||
Cell Line: |
HemSC cells |
|
Concentration: |
50μM,100μM,or 200μM |
|
Incubation Time: |
24 hours |
|
Result: |
Induced HemSC cell death occurred via an apoptotic pathway. |
|
体内研究 |
Propranolol (orally administration;40mg/kg;daily) significantly reduces the vessel diameter relative to the vehicle-treated implants,and increases the number of cells that expressed phosphorylated ERK1/2 within the IH Matrigel implant. |
|
Animal Model: |
A xenograft mouse model of IH (infantile hemangiomas) with HemSC cells |
|
Dosage: |
40mg/kg |
|
Administration: |
Orally administration;40mg/kg;daily |
|
Result: |
Improved vessel development in the IH mouse model that correlated with MAPK pathway activation. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )